Import from '@womanrx/ui'

Combined Oral Contraceptive vs Nurtec ODT: What to Do When One Fails

Why Women End Up on Both, or Stuck Choosing Between Them

These two medications treat different problems, but they collide in the lives of real women. A woman with PCOS may be prescribed a COC for cycle regulation and acne, then find her migraines escalate. A woman started on Nurtec ODT for migraine prevention may ask whether a COC could also manage her painful, irregular periods. And a woman in perimenopause may have been on a COC for years before a neurologist flags her newly documented aura and tells her to stop.

ACOG Practice Bulletin 206 classifies migraine with aura as a WHO Medical Eligibility Criteria Category 4 condition for estrogen-containing contraceptives, meaning the risks outweigh any benefit and the method should not be used. That single guideline is the most common reason women find themselves needing to switch or add rimegepant.

Understanding both drugs on their own terms first makes the comparison much cleaner.

What Combined Oral Contraceptives Actually Do in a Female Body

COCs suppress ovulation by delivering a fixed daily dose of synthetic estrogen (almost always ethinyl estradiol, typically 10 to 35 mcg) combined with a progestin. The hormonal suppression flattens the mid-cycle LH surge, thickens cervical mucus, and thins the endometrial lining.

Effects on the Menstrual Cycle and Hormonal Milieu

By creating a stable, low-estrogen environment, COCs eliminate the estrogen withdrawal that drives menstrual migraine for many women. That sounds helpful for migraine, and for some women it genuinely is. Extended or continuous COC regimens, which eliminate the hormone-free interval, can reduce menstrual migraine frequency. The problem is that the same synthetic estrogen raises the baseline risk of venous thromboembolism and, in women who have migraine with aura, may raise ischemic stroke risk by a factor of approximately six to eight compared to women with neither risk factor.

PCOS, Acne, and the Non-Contraceptive Reasons Women Use COCs

A 2011 review in the Journal of Clinical Endocrinology and Metabolism confirmed that COCs remain a first-line pharmacologic option for managing hyperandrogenism in PCOS, reducing free androgen index and improving acne and hirsutism. For a woman with PCOS who also has migraine, losing her COC is not simply a contraception problem. It may mean returning to irregular, painful cycles and worsening androgenic symptoms.

When a COC Fails or Becomes Unsafe

A COC "fails" in migraine management for several reasons:

• Migraine frequency or severity increases after starting the pill, particularly in the pill-free week
• A new or worsening aura develops (visual zigzags, speech changes, limb weakness lasting more than five minutes)
• A woman reaches perimenopause and her cardiovascular risk profile changes
• She decides to try to conceive

Any of these situations calls for a reassessment of the full medication plan, not just a pill swap.

What Rimegepant (Nurtec ODT) Actually Does in a Female Body

Rimegepant is a small-molecule CGRP (calcitonin gene-related peptide) receptor antagonist. It is the only migraine medication approved by the FDA for both acute treatment and preventive therapy in the same formulation and dose: 75 mg orally disintegrating tablet. FDA approval for the preventive indication was granted in May 2021.

How It Works and Why It Matters for Women

CGRP is released from trigeminal nerve endings during migraine attacks. Women have higher baseline CGRP levels than men across the menstrual cycle, and CGRP levels spike further around menstruation, which partially explains why migraine prevalence is roughly three times higher in women than men during the reproductive years. Blocking the CGRP receptor interrupts the neuroinflammatory cascade without the vasoconstrictive mechanism of triptans, which makes rimegepant a safer choice for women with cardiovascular risk factors or contraindications to triptans.

The Key Prevention Trial

The key preventive trial, BHV3000-305, was published in The Lancet in 2021. Participants took 75 mg rimegepant every other day for 12 weeks. At week 9 through 12, 44.4% of rimegepant users achieved a 50% or greater reduction in mean monthly migraine days, compared with 42.3% in the placebo group at the same endpoint, though the primary endpoint of mean change in monthly migraine days showed a statistically significant difference favoring rimegepant (reduction of 4.3 days vs 3.5 days, p = 0.0099). Women made up approximately 88% of the trial population, which is unusual and genuinely useful for the clinical interpretation of these results.

Does Rimegepant Affect Hormones or Cycles?

Rimegepant has no known hormonal activity. It does not affect estrogen, progesterone, androgens, or the hypothalamic-pituitary-ovarian axis. Women with PCOS, endometriosis, or perimenopausal hormonal fluctuation do not experience any cycle-related changes from rimegepant itself. This is a meaningful advantage when a woman needs to stop her COC.

Head-to-Head: What Each Drug Does Well and Where Each Falls Short

| Feature | COC | Rimegepant | |---|---|---| | Contraception | Yes | No | | Menstrual cycle regulation | Yes | No | | PCOS/androgenic symptom control | Yes | No | | Acute migraine relief | Sometimes (via cycle stabilization) | Yes (direct) | | Migraine prevention | Off-label, indirect | Yes (FDA-approved) | | Safe with migraine with aura | No (WHO MEC 4) | Yes | | Cardiovascular risk | Elevated (VTE, stroke in aura) | Minimal | | Safe in perimenopause with aura | No | Yes | | Hormonal effects | Yes (systemic) | None | | Pregnancy category | Contraindicated | Insufficient data |

The table makes clear that these drugs are not substitutes for each other in most women. A woman stopping a COC for migraine-safety reasons still needs contraception. A woman adding rimegepant for migraine still needs her COC if she has PCOS-related androgenism.

Sex-Specific Physiology: How the Menstrual Cycle Changes Everything

Menstrual Migraine and Estrogen Withdrawal

Pure menstrual migraine (attacks exclusively on days minus two to plus three of the cycle, with no other migraine days) affects approximately 7 to 14% of women with migraine, while menstrually related migraine affects closer to 50%. The trigger is estrogen withdrawal at the end of the luteal phase.

COC extended cycling can stabilize estrogen and reduce this withdrawal trigger. Rimegepant taken every other day can suppress the neuroinflammatory cascade regardless of hormonal timing. For a woman with menstrual migraine stopping her COC, switching to or adding every-other-day rimegepant is a mechanistically sound strategy, since the CGRP spike that accompanies estrogen withdrawal will still be blocked.

Perimenopause and the Changing Risk Calculus

Perimenopause brings erratic estrogen fluctuation, which is one reason migraine often worsens or begins in the late 30s and 40s. A perimenopausal woman who has been using a low-dose COC for contraception and cycle regulation faces a specific dilemma: she may need the cycle control, but if aura develops or worsens, her neurologist and gynecologist may disagree on management.

The WomanRx clinical framework for this transition: when a perimenopausal woman develops new or worsening aura on COC, the sequence is (1) stop the COC immediately, (2) obtain neurologist confirmation of aura diagnosis, (3) initiate a non-estrogen contraceptive method (progestin-only pill, IUD, or barrier), (4) evaluate whether every-other-day rimegepant for prevention plus an acute agent covers migraine, and (5) revisit whether transdermal low-dose estrogen for menopausal symptoms, which carries a different risk profile than oral synthetic estrogen, may be appropriate later. This four-to-five step framework does not appear in published guidelines in this precise sequence, but each individual step is evidence-based.

Reproductive Years: Migraine Prevalence Peaks at 35 to 45

Women between 35 and 45 represent the intersection of peak migraine prevalence, peak COC use, and peak aura-related stroke risk accumulation. Stroke risk in women with migraine with aura who smoke and use COC may be elevated up to 34-fold compared to women with none of these factors. Age alone raises VTE risk with COC. Rimegepant carries no such compounding risk.

Pregnancy and Lactation: The Section Every Woman Needs to Read

COC in Pregnancy

Stop COC before attempting conception. COCs are not teratogenic in the strict sense, but they are absolutely not indicated during pregnancy and must be discontinued. If a woman conceives while taking a COC, ACOG reassures that inadvertent first-trimester exposure does not warrant pregnancy termination, but the pill must be stopped immediately upon confirmed pregnancy. Ethinyl estradiol transfers into breast milk and may reduce milk supply; most lactating women are guided toward progestin-only methods.

Rimegepant in Pregnancy and Lactation

Rimegepant has no adequate human data in pregnancy. Animal reproductive studies at high doses showed embryo-fetal toxicity. The FDA labeling for Nurtec ODT advises avoiding use during pregnancy and recommends that women of reproductive potential discuss contraceptive needs with their clinician. Because rimegepant has no contraceptive effect, a woman who stops her COC and switches to rimegepant must use a separate, reliable contraception method if pregnancy is not desired.

Lactation data for rimegepant is limited. The label advises considering the developmental benefits of breastfeeding alongside the potential risks, but no strong human milk transfer studies have been published as of this writing. Women who are breastfeeding should discuss timing of rimegepant doses with their prescriber.

Trying to Conceive

A woman with migraine who is trying to conceive faces a specific gap: she needs to stop her COC, she cannot use rimegepant with confidence during the two-week wait or confirmed pregnancy, and her migraine may worsen due to the hormonal fluctuation of a normal ovulatory cycle after years of COC suppression. Magnesium supplementation at 400 mg daily has Level B evidence from the American Headache Society for migraine prevention and is considered safe in pregnancy, making it a useful bridge strategy.

Who This Approach Is Right For (and Who Should Pause)

Women for Whom Stopping COC and Starting Rimegepant Makes Clinical Sense

• Women with confirmed migraine with aura who need safer contraception (progestin-only options plus rimegepant for migraine)
• Perimenopausal women developing aura for the first time on COC
• Women who have failed two or more triptans and need a non-vasoconstricting preventive option
• Women with cardiovascular risk factors (hypertension, smoking, obesity, family history of early stroke) who currently use COC for non-contraceptive reasons

Women Who Should Not Simply Swap COC for Rimegepant

• Women using COC primarily for PCOS androgenic control: rimegepant does nothing for hyperandrogenism, acne, or cycle regulation. A dermatologic or endocrinologic alternative is needed alongside or instead.
• Women using COC for endometriosis-related cycle suppression: the surgical and hormonal management of endometriosis is entirely separate from migraine management.
• Women who need contraception: rimegepant is not a contraceptive. Full stop.
• Women with hepatic impairment: rimegepant is metabolized by CYP3A4 and should be avoided with strong CYP3A4 inhibitors (clarithromycin, itraconazole). COC interactions with enzyme-inducing drugs (rifampin, topiramate, some anticonvulsants) are a separate consideration.

Women Who May Benefit From Both Simultaneously

A woman with PCOS and migraine without aura who tolerates her COC well may benefit from adding every-other-day rimegepant for migraine prevention while continuing her COC for PCOS management and contraception. In this scenario, no significant drug-drug interaction between ethinyl estradiol/progestin combinations and rimegepant has been identified in the prescribing literature, though women should be monitored for any change in migraine frequency after initiating both.

When a COC Fails for Migraine: The Practical Decision Tree

A COC "fails" for migraine in one of three ways: it makes migraines worse, it stops making them better, or it becomes medically contraindicated. Each scenario calls for a different next step.

Scenario 1: COC Makes Migraines Worse

The pill-free week is the most common culprit. Estrogen withdrawal triggers attacks. Options: switch to extended or continuous cycling to eliminate the hormone-free interval, or stop the COC and transition to rimegepant plus a non-hormonal or progestin-only contraceptive. A progestin-only pill (WHO MEC Category 2 for migraine with aura) carries a far lower stroke risk than COC.

Scenario 2: COC Stops Helping and Migraine Burden Increases

This often happens in perimenopause when the underlying hormonal chaos overwhelms the stabilizing effect of the pill. Adding or switching to every-other-day rimegepant addresses the CGRP pathway directly. The preventive benefit builds over eight to twelve weeks, so triptans or a different acute agent should remain available during the transition.

Scenario 3: COC Becomes Contraindicated

New aura diagnosis, significant hypertension, upcoming surgery requiring immobilization, a VTE event: any of these makes continuing COC medically untenable. Immediate discontinuation is required. Rimegepant can be initiated at the same time with no washout needed. Non-estrogen contraception must be in place before the first pill-free cycle if pregnancy is not desired.

When Rimegepant Fails: What Comes Next

Rimegepant preventive therapy is considered to have failed if monthly migraine days do not decrease by at least 50% after twelve weeks of every-other-day dosing, or if acute use does not provide two-hour pain freedom in the majority of attacks. At that point, the options include:

• Switching to a monthly or quarterly injectable CGRP monoclonal antibody (erenumab, fremanezumab, galcanezumab), which have larger prevention trial datasets though similar mechanisms
• Adding a non-CGRP preventive (topiramate, amitriptyline, propranolol), noting that topiramate reduces COC efficacy and is a Category D teratogen requiring two forms of contraception
• Reassessing the hormonal environment, because perimenopausal estrogen fluctuation may be driving CGRP-independent migraine mechanisms

If rimegepant fails acutely (does not relieve the headache within two hours), adding a triptan on a different migraine day is not contraindicated, but combining rimegepant and a triptan in the same attack has limited safety data. The FDA label advises caution.

The Evidence Gap: What We Still Do Not Know for Women

Women make up the vast majority of migraine sufferers and the majority of rimegepant trial participants, which is a welcome exception to the historical norm. But specific data gaps remain:

• No published trials have directly studied rimegepant in women with PCOS-associated migraine or compared outcomes in women with versus without COC use at baseline.
• The interaction between endogenous estrogen fluctuation in perimenopause and rimegepant efficacy has not been studied prospectively.
• Long-term rimegepant safety data beyond twelve months is sparse for any population, and female-specific long-term data (bone density, ovarian reserve, cardiovascular markers) have not been published.
• Postpartum migraine, which affects up to 34% of women in the first six weeks after delivery due to estrogen withdrawal, has not been studied with rimegepant in lactating women.

Acknowledging these gaps is not a reason to avoid rimegepant. It is a reason to document the decision carefully, revisit it at each appointment, and watch for emerging data.

Practical Switching Guide

If your clinician has advised stopping your COC and you have migraine, ask these specific questions before leaving the appointment:

1. What contraceptive method will replace the COC, and when should it start?
2. Should rimegepant be used for acute treatment, prevention, or both?
3. How long before you assess whether rimegepant prevention is working?
4. What acute backup do I use during the transition (triptan, NSAID, rimegepant on-demand)?
5. If I have PCOS or acne managed by the COC, what replaces that function?

Bring a three-month headache diary to this conversation. The diary should log headache days, severity, menstrual cycle days, and any acute medications used. This data is what allows a clinician to distinguish menstrual migraine from migraine with aura from tension headache, and it determines whether rimegepant's every-other-day regimen or on-demand use makes more sense for your pattern.

The Migraine Trust's patient-facing headache diary validated in clinical settings records all three variables in a single-page format your clinician can read in under two minutes.